![Christopher Cargill](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 936 628 $ al 31/08/2026
Christopher Robert Cargill is currently Director at Nxera Pharma Japan Co., Ltd. Formerly, Mr. Cargill was Director at Sosei R&D Ltd.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
Nxera Pharma Co., Ltd.
 Nxera Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Develops bio pharmaceutical products 0,14 % | 31/12/2025 | 131.668 ( 0,14 % ) | 936 628 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
Idorsia Pharmaceuticals Japan Ltd.
 Idorsia Pharmaceuticals Japan Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells daridorexants | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
Sosei R&D Ltd.
 Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
Sosei R&D Ltd.
Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Idorsia Pharmaceuticals Japan Ltd.
Idorsia Pharmaceuticals Japan Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells daridorexants | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
